Allogene Therapeutics Inc

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Allogene Therapeutics reports strong Q4 performance and financial stability

Allogene Therapeutics showcased promising clinical data for its AlloCAR T therapy and emphasized a strong financial position. While facing challenges in manufacturing optimization, the company is focused on pivotal trials and cost management. Opportunities for growth include product reintroductions and ongoing program updates.

Allogene reports positive Q1 results, eyes partnerships for growth

Allogene Therapeutics showcased positive patient responses and financial prudence in Q1 2023, underlining its commitment to innovation and efficiency.
While facing resource limitations and challenges in product development, the company is exploring partnerships and expansion opportunities for future growth.
Overall, Allogene's strategic focus on patient care, operational excellence, and therapeutic advancements positions it well for continued success in the biopharmaceutical industry.

Allogene Therapeutics reports Q2 losses but showcases promising CAR-T results

Allogene Therapeutics' Q2 2023 performance reflects strategic investments in R&D and operational expenses, supported by a strong balance sheet and promising results in their allogeneic CAR-T program.
While facing challenges in patient access, manufacturing, and collaborations, the company is well-positioned to capitalize on opportunities in global expansion, next-gen technologies, and clinical trial progress.
With a focus on innovation, operational efficiency, and market expansion, Allogene Therapeutics navigates complexities in the CAR-T space to drive growth and advance its therapeutic offerings.

Allogene Therapeutics excels in Q3, poised for CAR T leadership

Allogene Therapeutics showcased strong financials, promising clinical trial results, and strategic leadership changes.
The focus on allogeneic CAR T therapy positions the company for growth and market leadership.
Challenges include competition, regulatory complexities, and ensuring manufacturing scalability.
Opportunities lie in expanding trials, presenting at key conferences, and advancing pipeline innovations.

Allogene Therapeutics reports robust financials and advances innovative therapies

Allogene Therapeutics showcased strong financials, innovative trials, and strategic partnerships, positioning the company for future growth and therapeutic advancements.
While facing challenges from external factors and clinical complexities, Allogene has opportunities to expand its therapeutic reach and enhance treatment efficacy.
Investor interest in Allogene's pipeline and the company's positive response to inquiries reflect a promising outlook for continued development and success.
Allogene's focus on cutting-edge therapies, financial stability, and community engagement underscore its commitment to advancing patient care and addressing unmet medical needs.

Allogene Therapeutics reports strong Q1 performance and eyes autoimmune expansion

Allogene Therapeutics demonstrated solid financial performance in Q1 2024, with strategic investments and a focus on core programs.
Challenges in enrollment processes, dosing strategies, and safety considerations underscore the complexities of therapeutic development.
Opportunities lie in expanding into autoimmune indications, leveraging unique treatment approaches, and impacting the CAR T treatment landscape.

Allogene Therapeutics reports Q2 momentum, faces challenges, eyes growth

Allogene Therapeutics demonstrated positive momentum and strategic planning in Q2 2024, focusing on key programs and collaborations.
While financial challenges exist, the company's strengths in manufacturing capabilities and program advancements provide a solid foundation.
Addressing challenges like differentiation in the autoimmune space and financial losses will be crucial for sustained growth.
Opportunities for growth are present in continued program progress, FDA collaborations, and strategic milestones like IND filings.

Allogene Therapeutics advances in CAR-T therapies amidst financial challenges

Allogene Therapeutics showcased promising advancements in Q3 2024 across multiple therapeutic areas, positioning itself as a key player in the CAR-T therapy space.
While financial challenges persist, the company's strong cash position and strategic focus on transformative therapies provide a solid foundation for future growth.
Addressing concerns raised by analysts regarding data, safety, and trial participation will be crucial for maintaining investor confidence and advancing clinical development.
Overall, Allogene's dedication to pioneering treatments in oncology and autoimmune diseases underscores its potential for long-term success and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allogene is a leading allogeneic CART developer. It is slowly delivering strong data for its programs.

Allogene: Continuing To Deliver Solid Data In Allogeneic CART

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

Why Is Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report?

The stock price of Allogene Therapeutics has seen a 13% drop over the last five trading days. The decline is surprising given the company's announcement of positive results from early clinical trials for its CAR-T treatment for blood cancer.

Allogene Therapeutics Looks Attractive After A 13% Fall Last Week

SOUTH SAN FRANCISCO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will discuss progress on its AlloCAR T platform during today's virtual CD19 Forum. The Forum will include results from Phase 1 ALPHA (ALLO-501) and ALPHA2 (ALLO-501A) trials in relapsed/refractory non-Hodgkin lymphoma (NHL), developed in collaboration with Servier, as well as safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from ALLO-647. ALLO-647 is part of the Company's differentiated lymphodepletion regimen. The Forum will also discuss the Company's approach for optimizing the unique benefits of its allogeneic CAR T therapy platform and the potential role of AlloCAR T therapy in NHL based upon views from clinical trial investigators and early market research.

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will discuss progress on its AlloCAR T platform during a virtual CD19 Forum on May 19, 2021 at 2:30 PM Pacific Time/5:30 PM Eastern Time. The Forum will include results from Phase 1 ALPHA (ALLO-501) and ALPHA2 (ALLO-501A) trials in relapsed/refractory non-Hodgkin lymphoma, developed in collaboration with Servier. The Company will also share safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from ALLO-647, a component of its differentiated lymphodepletion regimen.

Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021

Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.

Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2021 Results - Earnings Call Transcript

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 47.92% and 56.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) Reports Q1 Loss, Tops Revenue Estimates

Allogene Therapeutics Reports First Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif. and PARIS, April 28, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an independent international pharmaceutical company, today announced that longer-term follow-up data from Allogene's dose escalation Phase 1 ALPHA study of ALLO-501 in relapsed/refractory non-Hodgkin lymphoma (NHL) will be jointly presented with initial data from the ALPHA2 trial of ALLO-501A at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually June 4 - 9, 2021. A separate poster presentation will detail safety and biomarker findings from ALLO-647, Allogene's wholly owned antibody used for lymphodepletion with fludarabine (Flu)/cyclophosphamide (Cy) in patients with relapsed/refractory non-Hodgkin lymphoma and multiple myeloma.

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021

FDA grants RMAT designation to Allogene's (ALLO) CAR T cell product candidate for multiple myeloma, ALLO-715. The designation will help accelerate development and review of the candidate.

Allogene (ALLO) CAR T Therapy for Myeloma Gets FDA RMAT Tag

SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-715 in relapsed/refractory multiple myeloma. The FDA granted RMAT designation based on the potential of ALLO-715 to address the growing unmet need for patients who have failed other multiple myeloma therapies.

Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to study ALLO-605 for the treatment of patients with relapsed or refractory multiple myeloma. ALLO-605 is part of the company's multi-faceted strategy to develop an allogeneic CAR T therapy targeting BCMA for the treatment of multiple myeloma. The Phase I IGNITE trial will evaluate escalating doses of ALLO-605 beginning in mid-2021.

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn., April 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in a Phase 1 trial evaluating ALLO-715, Allogene's investigational anti-B-cell maturation antigen (BCMA) AlloCAR T therapy, in combination with nirogacestat, SpringWorks' investigational gamma secretase inhibitor (GSI), in patients with relapsed or refractory multiple myeloma.

Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced preclinical data at the American Association for Cancer Research (AACR) Annual Meeting that expands the utility of its TurboCAR™ technology platform to address specific biology of solid tumor oncology.

Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting

Allogene is a world leader in allogeneic CAR-T.

Allogene: World Leader In Allogeneic CAR-T

Allogene Therapeutics (ALLO) Up 3% Since Last Earnings Report: Can It Continue?

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2020 Results - Earnings Call Transcript

Allogene (ALLO) reports no revenues for the fourth quarter of 2020.

Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported fourth quarter and full year financial results for the periods ended December 31, 2020.

Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Novartis

Seelos Therapeutics

Selecta Biosciences

Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S.-based clinical-stage immuno-oncology company.

Why Novartis, Seelos Therapeutics And More Are Moving Today

SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that Ton Schumacher, Ph.D., Principal Investigator at the Netherlands Cancer Institute and chair of Allogene's Scientific Advisory Board, has been awarded the 2021 Jeantet-Collen Prize for Translational Medicine. The award is presented every year by the Louis-Jeantet Foundation to distinguish leading-edge researchers in Europe, foster scientific excellence, and honor awardees conducting fundamental and translational research that is of considerable significance for medicine.

Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine

The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.

News for Allogene Therapeutics Inc Stock (ALLO)